On the Forefront of Thoracic Cancer Treatment Advances
FDA Grants Bemcentinib Fast Track Designation for NSCLC Treatment
November 15, 2021
The FDA granted Fast Track designation to bemcentinib when combined with an anti-PD-L1 agent for patients with STK11 altered advanced/metastatic non-small cell lung cancer without actionable mutations...
5 Years Later: Pembrolizumab Has Superior Overall Survival Compared to Chemotherapy in NSCLC
December 9, 2021A 5-year follow-up of pembrolizumab monotherapy for patients with PD-L1 positive, locally advanced, or metastatic non-small-cell lung cancer without EGFR/ALK alterations showed higher overall survival rates as well as a durable response when compared to chemotherapy...
Pralestinib Approved in Europe for RET Fusion-Positive Advanced NSCLC
December 6, 2021The European Commission granted conditional marketing authorization for pralestinib to treat adults with RET fusion-positive advanced non-small cell lung cancer who have not been treated previously with a RET inhibitor...
.jpg "Atezolizumab, Nivolumab Tied to Longer Survival than Docetaxel in Advanced Lung Cancer")
Atezolizumab, Nivolumab Tied to Longer Survival than Docetaxel in Advanced Lung Cancer
December 2, 2021Patients with advanced non-small-cell lung cancer (NSCLC) who are treated with atezolizumab or nivolumab appear to survive longer than those treated with docetaxel...
Exposure to Leukotriene Inhibitors Linked to Reduced Risk for Lung Cancer
December 1, 2021New research has found a promising link between exposure to leukotriene inhibitors and a reduction in the risk of lung cancer...
Nivolumab Improved Event-free Survival in NSCLC Patients
November 17, 2021A phase 3 clinical trial evaluating nivolumab plus chemotherapy as a neoadjuvant treatment for patients with stage IB to IIIA resectable non-small cell lung cancer met its primary endpoint of improved event-free survival...
